Lazy Eye Market Research Report – Global Forecast till 2027

Global Lazy Eye Market Research Report: By Type (Strabismic, Refractive, Deprivation Amblyopia) Diagnosis (General Eye Test, Squint Test) Treatment (Corrective Eyewear, Eye Patches, Atropine Drops) End-Users (Retail Pharmacies) – Global Forecast Till 2027

ID: MRFR/MED/4099-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2018-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario


The lazy eye disease or amblyopia is a childhood condition affecting the development of vision. In this disease, it the brain does not acknowledge the images seen by the eye. The condition affects only one of the eye but can further result in the impairment of vision in the other eye. Increasing prevalence of the lazy eye diseases and growing child population are the major drivers for the market growth during the forecast period. According to the National Health Service, U.K, 1 in every 50 children is predicted to develop a lazy eye. Moreover, in 2016, it was reported that there were approximately 4014.3 million children within the U.K. Additionally, rising healthcare expenditures and increasing R&D by the major market players fuel the market growth. However, lack of awareness and unavailability of the effective treatment procedures may restrain the market growth during the forecast period.


The lazy eye market is expected to grow at an approximate CAGR of 7.8% during the forecast period.


Figure 1:- Global Lazy Eye Market Share, By Region


 Lazy Eye Market


Sources: WHO, annual reports, press release, white paper, and company presentation


Segmentation


The global lazy eye market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of the type, the market is segmented into strabismic amblyopia, refractive amblyopia, deprivation amblyopia, and others. On the basis of the diagnosis, the market is segmented into general eye test, squint test, and others. On the basis of the treatment, the market is segmented into corrective eyewear, eye patches, surgery, atropine eye drops, and others. The corrective eyewear segment is sub-segmented into glasses, contact lenses, and others. On the basis of the end-users, the market is segmented into eye care clinics, hospitals, retail pharmacies, and others.


Research Methodology


 Lazy Eye Market Research methodology


Sources: WHO, annual reports, press release, white paper, and company presentation


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Regional Analysis


The Americas dominate the global lazy eye market owing to the well-developed healthcare sector, growing child population, and rising healthcare expenditure. According to the Annie E. Casey Foundation in 2016, the child population (0-4 years) in the U.S. was estimated to be around 19927 million. Moreover, the presence of leading market players in the region fuels the market growth.


Europe is the second largest global lazy eye market. Availability of funds for research and huge patient population are the major drivers of the market growth within the region. On the regional basis, the European market for lazy eye is segmented into Western Europe and Eastern Europe. Presence of the developed economies like Germany, Italy, France within the regions enables Western Europe to lead the market. On the other hand, Eastern Europe is estimated to be the fastest growing region.


The Asia Pacific region is the fastest growing region owing to the developing healthcare sector and rising per capita healthcare expenditure. Moreover, the presence of the developed economies like India and China within the region fuels the market. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was estimated to be one of the fastest growing sectors and was expected to advance at an approximate CAGR of 22.87% from 2015-2020 and reach USD 280 billion by the year 2020.


The Middle East & Africa holds the least share in the lazy eye market due to the poor availability of the healthcare services and low per capita healthcare expenditures within the African region. On the other hand, the Middle East is estimated to be the fastest growing region during the projected period, 2017-2023.


Key players in global lazy eye market


The key players in the global lazy eye market are inclusive of Pfizer Inc. (U.S.), TCI Chemicals (India) Pvt. Ltd. (India), Adwia Pharmaceuticals Co. (Egypt), 3M (U.S.), Bausch & Lomb Incorporated. (U.S.), Rebion (U.S.), Vivid Vision, Inc. (U.S.), Johnson and Johnson Services, Inc. (U.S.), and others.



Frequently Asked Questions (FAQ) :


Lazy eye market can exhibit a CAGR of 7.8% from 2017 to 2023.

High prevalence of vision development disorders, investments in R&D, and large healthcare expenditure are major drivers of the global lazy eye market..

Unavailability of treatments in developing economies can restrain the global lazy eye market growth.

APAC can display a robust growth rate in the global lazy eye market till 2023 due to developments in the healthcare sector and rise in healthcare expenditure.

3M, TCI Chemicals (India) Pvt. Ltd., Pfizer Inc., Bausch & Lomb Incorporated., Johnson and Johnson Services, Inc., Rebion, Adwia Pharmaceuticals Co., and Vivid Vision, Inc. are key players of the global lazy eye market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Diagnosis Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Lazy Eye Market, By Type

6.1 Introduction

6.2 Strabismic Amblyopia

Market Estimates & Forecast, 2017 – 2023

6.3 Refractive Amplyopia

Market Estimates & Forecast, 2017 – 2023

6.4 Deprivation Amblyopia

Market Estimates & Forecast, 2017 – 2023

6.5 Others

Chapter 7. Global Lazy Eye Market, By Diagnosis

7.1 Introduction

7.2 General Eye Test

Market Estimates & Forecast, 2017 – 2023

7.3 Squint Test

Market Estimates & Forecast, 2017 – 2023

7.4 Others

Chapter 8. Global Lazy Eye Market, By Treatment

8.1 Introduction

8.2 Corrective Eyewear

Market Estimates & Forecast, 2017 – 2023

8.2.1 Glasses

8.2.2 Contact Lenses

8.3 Eye Patches

Market Estimates & Forecast, 2017 – 2023

8.4 Surgery

Market Estimates & Forecast, 2017 – 2023

8.5 Atropine Eye Drops

Market Estimates & Forecast, 2017 – 2023

Chapter 9. Global Lazy Eye Market, By End Users

9.1 Introduction

9.2 Eye Care Clinics

Market Estimates & Forecast, 2017 – 2023

9.3 Hospitals

Market Estimates & Forecast, 2017 – 2023

9.4 Retail Pharmacies

Market Estimates & Forecast, 2017 – 2023

9.5 Others

Chapter 10. Global Lazy Eye Market, By Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest Of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic Of Korea

10.4.6 Rest Of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest Of The Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 3M

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Adwia Pharmaceuticals Co.

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Bausch & Lomb Incorporated.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Johnson And Johnson Services, Inc.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Pfizer Inc.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial Overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Rebion

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 TCI Chemicals (India) Pvt. Ltd.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Vivid Vision, Inc.

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs Of The Market

13.2 Key Companies To Watch

13.3 Prediction Of Lazy Eye Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Lazy Eye Industry Synopsis, 2017 – 2023

Table 2 Global Lazy Eye Market Estimates And Forecast, 2017 – 2023, (USD Million)

Table 3 Global Lazy Eye Market By Region, 2017 – 2023, (USD Million)

Table 4 Global Lazy Eye Market By Type, 2017 – 2023, (USD Million)

Table 5 Global Lazy Eye Market By Diagnosis, 2017 – 2023, (USD Million)

Table 6 Global Lazy Eye Market By Treatment, 2017 – 2023, (USD Million)

Table 7 Global Lazy Eye Market By End Users, 2017 – 2023, (USD Million)

Table 8 North America Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 9 North America Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 10 North America Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 11 North America Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 12 U.S. Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 13 U.S. Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 14 U.S. Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 15 U.S. Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 16 Canada Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 17 Canada Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 18 Canada Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 20 South America Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 21 South America Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 22 South America Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 23 South America Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 24 Europe Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 25 Europe Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 26 Europe Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 28 Western Europe Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 29 Western Europe Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 30 Western Europe Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 31 Western Europe Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 35 Eastern Europe Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 39 Asia Pacific Lazy Eye By End Users, 2017 – 2023, (USD Million)

Table 40 Middle East & Africa Lazy Eye By Type, 2017 – 2023, (USD Million)

Table 41 Middle East & Africa Lazy Eye By Diagnosis, 2017 – 2023, (USD Million)

Table 42 Middle East & Africa Lazy Eye By Treatment, 2017 – 2023, (USD Million)

Table 43 Middle East & Africa Lazy Eye By End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Global Lazy Eye Market

Figure 3 Market Dynamics For Global Lazy Eye Market

Figure 4 Global Lazy Eye Market Share, By Type 2020

Figure 5 Global Lazy Eye Market Share, By Diagnosis 2020

Figure 6 Global Lazy Eye Market Share, By Treatment, 2020

Figure 7 Global Lazy Eye Market Share, By End Users, 2020

Figure 8 Global Lazy Eye Market Share, By Region, 2020

Figure 9 North America Lazy Eye Share, By Country, 2020

Figure 10 Europe Lazy Eye Share, By Country, 2020

Figure 11 Asia Pacific Lazy Eye Share, By Country, 2020

Figure 12 Middle East & Africa Lazy Eye Share, By Country, 2020

Figure 13 Global Lazy Eye Market: Company Share Analysis, 2020 (%)

Figure 14 3M: Key Financials

Figure 15 3M: Segmental Revenue

Figure 16 3M: Geographical Revenue

Figure 17 Adwia Pharmaceuticals Co.: Type UK Ltd: Key Financials

Figure 18 Adwia Pharmaceuticals Co.: Segmental Revenue

Figure 19 Adwia Pharmaceuticals Co.: Geographical Revenue

Figure 20 Bausch & Lomb Incorporated.: Key Financials

Figure 21 Bausch & Lomb Incorporated.: Segmental Revenue

Figure 22 Bausch & Lomb Incorporated.: Geographical Revenue

Figure 23 Johnson And Johnson Services, Inc.: Key Financials

Figure 24 Johnson And Johnson Services, Inc.: Segmental Revenue

Figure 25 Johnson And Johnson Services, Inc.: Geographical Revenue

Figure 26 Pfizer Inc.: Key Financials

Figure 27 Pfizer Inc.: Segmental Revenue

Figure 28 Pfizer Inc.: Geographical Revenue

Figure 29 Rebion : Key Financials

Figure 30 Rebion: Segmental Revenue

Figure 31 Rebion: Geographical Revenue

Figure 32 TCI Chemicals (India) Pvt. Ltd.: Key Financials

Figure 33 TCI Chemicals (India) Pvt. Ltd.: Segmental Revenue

Figure 34 TCI Chemicals (India) Pvt. Ltd.: Geographical Revenue

Figure 35 Vivid Vision, Inc.: Key Financials

Figure 36 Vivid Vision, Inc.: Segmental Revenue

Figure 37 Vivid Vision, Inc.: Geographical Revenue